QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
QQQ   274.55 (+0.99%)
AAPL   461.35 (+2.06%)
MSFT   210.96 (+0.85%)
FB   263.17 (+1.26%)
GOOGL   1,528.03 (+1.38%)
AMZN   3,203.59 (+1.31%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.00 (-1.22%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
Log in

NYSE:DPLODiplomat Pharmacy Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$4.00
0.00 (0.00 %)
(As of 02/7/2020)
Add
Compare
Today's Range
$4.00
Now: $4.00
$4.01
50-Day Range
$4.00
MA: $4.00
$4.00
52-Week Range
$2.43
Now: $4.00
$14.46
Volume744,968 shs
Average Volume545,194 shs
Market Capitalization$304 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.
Read More
Diplomat Pharmacy logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.8Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars


Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.60 per share
Book Value$6.24 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$304 million
Next Earnings DateN/A
OptionableOptionable

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Diplomat Pharmacy?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Diplomat Pharmacy
.

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.35) EPS for the quarter, missing the consensus estimate of ($0.20) by $2.15. The business had revenue of $1.30 billion for the quarter, compared to analysts' expectations of $1.17 billion. Diplomat Pharmacy had a negative return on equity of 12.15% and a negative net margin of 12.47%. Diplomat Pharmacy's revenue was down 5.3% compared to the same quarter last year.
View Diplomat Pharmacy's earnings history
.

What price target have analysts set for DPLO?

6 Wall Street analysts have issued 12-month price targets for Diplomat Pharmacy's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $3.75 in the next twelve months. This suggests that the stock has a possible downside of 6.3%.
View analysts' price targets for Diplomat Pharmacy
.

Has Diplomat Pharmacy been receiving favorable news coverage?

News headlines about DPLO stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a daily sentiment score of -4.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Diplomat Pharmacy
.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the following people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $4.00.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $304 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is www.diplomatpharmacy.com.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.